Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Viridian Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 136 | 2 | 138 | +4 |
| Shares | 71.0M | 253.5K | 69.6M | −1.13M (−1.6%) |
| Value | $1.24B | $4.44M | $906.2M | −$333.2M (−26.9%) |
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Affinity Asset Advisors, LLC | 150,000 | $1.95M | 0.31% |
| SG Americas Securities, LLC | 46,056 | $599.0K | 0.00% |
| Trexquant Investment LP | 41,824 | $544.1K | 0.01% |
| Corebridge Financial, Inc. | 33,664 | $438.0K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 31,490 | $408.4K | 0.00% |
| Macquarie Group Ltd | 29,370 | $382.0K | 0.00% |
| Belvedere Trading LLC | 28,720 | $373.6K | 0.02% |
| Bayesian Capital Management, LP | 28,682 | $373.2K | 0.04% |
| Graham Capital Management, L.P. | 22,444 | $292.0K | 0.01% |
| Capstone Investment Advisors, LLC | 21,016 | $273.4K | 0.01% |
| Ameriprise Financial Inc | 20,985 | $273.0K | 0.00% |
| Nebula Research & Development LLC | 18,897 | $245.8K | 0.04% |
| Jump Financial, LLC | 18,800 | $244.6K | 0.00% |
| Bridgefront Capital, LLC | 15,709 | $204.4K | 0.09% |
| Alpine Global Management, LLC | 13,794 | $179.5K | 0.03% |
| Teacher Retirement System of Texas | 10,324 | $134.0K | 0.00% |
| Group One Trading, L.P. | 9,864 | $128.3K | 0.00% |
| EntryPoint Capital, LLC | 5,569 | $72.5K | 0.03% |
| Clearstead Advisors, LLC | 126 | $1.64K | 0.00% |
| CWM, LLC | 92 | $1.00K | 0.00% |
Sold out (16)
Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Logos Global Management LP | 700,000 | $12.3M |
| MPM Oncology Impact Management LP | 614,010 | $10.8M |
| Cutter Capital Management, LP | 278,638 | $4.88M |
| Cubist Systematic Strategies, LLC | 69,430 | $1.22M |
| Mirae Asset Global Investments Co., Ltd. | 28,822 | $628.7K |
| Lighthouse Investment Partners, LLC | 28,406 | $497.4K |
| American International Group, Inc. | 24,515 | $429.3K |
| E Fund Management Co., Ltd. | 19,323 | $338.3K |
| Bellevue Group AG | 19,100 | $334.4K |
| Metropolitan Life Insurance Co | 2,632 | $46.1K |
| Orion Capital Management LLC | 200 | $3.50K |
| Lindbrook Capital, LLC | 187 | $3.27K |
| Harbour Investments, Inc. | 66 | $1.16K |
| Fortitude Family Office, LLC | 29 | $508 |
| Game Plan Financial Advisors, LLC | 13 | $228 |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 8 | $140 |
Not filed for Q2 2024 yet (2)
Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Kopp LeRoy C | 205,640 | $3.60M |
| Credit Suisse AG | 47,877 | $838.3K |